deltatrials
Unknown PHASE2 NCT02016287

Sequential Paclitaxel Chemotherapy and Radiotherapy as 1st Line Treatment for Elderly Esophageal Squamous Cell Cancer

Sequential Paclitaxel Chemotherapy and Radiotherapy as First Line Treatment for Elderly Metastatic Esophageal Squamous Cell Cancer:: a Phase II Single Center Prospective Clinical Trial

Sponsor: Shen Lin

Conditions Elderly Patients Esophageal Squamous Cell Cancer
Interventions Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy
Updated 5 times since 2017 Last updated: Dec 13, 2013 Started: Dec 31, 2013 Primary completion: Dec 31, 2015 Completion: Jul 31, 2016

Listed as NCT02016287, this PHASE2 trial focuses on Elderly Patients and Esophageal Squamous Cell Cancer and remains ongoing. Sponsored by Shen Lin, it has been updated 5 times since 2013, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Jan 2021 — Jul 2024 [monthly]

    Unknown Status PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Unknown Status PHASE2

  5. Jan 2017 — Jun 2018 [monthly]

    Unknown Status PHASE2

    First recorded

Dec 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Shen Lin
Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Beijing, China